Drug intelligence / Profile preview

RE-01

Development stage: Unknown
Lead developer: ReEir
Modality: Cell Therapies
Administration: Intralesional

Overview

RE-01 is an autologous cell therapy consisting of ex vivo cultured peripheral blood mononuclear cells (PBMCs), developed by ReEir Co., Ltd. It is designed to induce therapeutic angiogenesis in patients with refractory, non-healing ischemic lower extremity ulcers, particularly those who are not candidates for surgical or endovascular revascularization. The therapy involves collecting a patient's own PBMCs, culturing them to enhance their regenerative and angiogenic properties, and then injecting them intralesionally into the affected area. RE-01 is currently being evaluated in Phase II clinical trials for conditions such as Buerger's disease and various collagen-vascular diseases, including systemic sclerosis and systemic lupus erythematosus.

Other names: ex vivo cultured peripheral blood mononuclear cells

Beyond the preview

Go deeper on RE-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RE-01.

Explore the full profile